Newcourt Acquisition Corp
NCACU
NASDAQ Global Market5.16
USD
-0.74
- -
CIK
0001849475
ISIN
KYG6448C1116
CUSIP
G6448C111
Return %
Stock
S&P500
1Y
-51.00
18.21
3Y
-48.66
64.38
5Y
-48.66
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Marc Gregory Balkin
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 2201 Broadway Oakland CA United States of America 94612
- IPO Date
- Oct 20, 2021
- CIK
- 0001849475
- Similar Companies
- Business
- Newcourt Acquisition Corp (NCACU) is a blank check company, or special purpose acquisition company (SPAC), whose principal business activity is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, with a focus on digital financial services and fintech companies with exposure to emerging markets. The company does not have significant operations other than seeking such a combination; it offers no products or services beyond its SPAC structure, including Class A ordinary shares, redeemable warrants and units traded on Nasdaq under the symbols NCAC, NCACW and NCACU. Incorporated in 2021 under the laws of the Cayman Islands and headquartered at 2201 Broadway, Suite 705, Oakland, California, it operates principally in the United States while targeting global opportunities, particularly in emerging markets supported by demographic growth and technology-enabled financial shifts; Newcourt Acquisition Corp functions as a subsidiary of Newcourt SPAC Sponsor LLC. In January 2024, Newcourt Acquisition Corp completed a reverse merger transaction, or de-SPAC, with Psyence Biomedical Ltd., a life science biotechnology company developing natural psilocybin-based therapeutics for palliative care and mental health indications including adjustment disorder, anxiety and depression; following shareholder approval on January 18, 2024, and closing on or about January 25, 2024, Psyence Biomedical Ltd. assumed the public listing on Nasdaq under the new ticker symbol PBM, with Newcourt's legacy units (NCACU) marked as potentially delisted thereafter. The business combination valued Psyence Biomedical at a pre-money equity value of approximately $50 million, with minimum net cash proceeds of $20 million from Newcourt's trust account after redemptions of about $10.7 million, supplemented by up to $10 million in senior secured convertible note financing; Psyence Group Inc., the parent entity, retained significant ownership and board control of the combined company, which continues Psyence Biomedical's Phase IIb clinical trials of lead candidate PEX010 (natural psilocybin capsule) in Australia. No further major acquisitions, funding rounds or strategic shifts for the standalone Newcourt entity have occurred since the merger, with its legacy ticker NCACU now inactive as of December 2025.